Etanercept Combined with Glucocorticoid and Gamma Globulin for Treating Children with Toxic Epidermal Necrolysis: A Case Report
Yanhua Fu,Yuanyuan Xiao,Tianji Gao,Junxiu Zhang,Tianjiao Wang
DOI: https://doi.org/10.2147/ccid.s440476
2024-01-24
Clinical Cosmetic and Investigational Dermatology
Abstract:Yanhua Fu, 1 Yuanyuan Xiao, 2 Tianji Gao, 1 Junxiu Zhang, 3 Tianjiao Wang 1 1 Department of Rheumatology, Baoding Hospital of Beijing Children's Hospital, Baoding, 071000, People's Republic of China; 2 Department of Dermatology, National Center for Children's Health (Beijing) Children's Hospital Affiliated to Capital Medical University, Beijing, 100045, People's Republic of China; 3 Department of Dermatology, Baoding Hospital of Beijing Children's Hospital, Baoding, 071000, People's Republic of China Correspondence: Yuanyuan Xiao, Department of Dermatology, National Center for Children's Health (Beijing) Children's Hospital Affiliated to Capital Medical University, No. 56 of Nanlishi Road, Xicheng District, Beijing, 100045, People's Republic of China, Tel +86 10 59612345, Email Toxic epidermal necrolysis (TEN) is a type of drug eruption in dermatology emergencies that is rare in clinical practice but has a high mortality rate. The main causes are drug and viral infections. Unfortunately, no expert consensus on treating this disease exists, and a standard therapy is absent. Up to now, glucocorticoids combined with gamma globulin are commonly used in clinical practice, but their efficacy is highly controversial. This study reports on a 7-year-old girl with TEN who did not respond to traditional therapy, such as methylprednisolone combined with gamma globulin, but was finally cured with an additional low-dose etanercept. The results showed that etanercept therapy in paediatric TEN is safe, reliable and worth recommending. Keywords: child toxic epidermal necrolysis, etanercept, glucocorticoids, gamma globulin Toxic epidermal necrolysis (TEN) is a potentially life-threatening delayed hypersensitivity reaction primarily triggered by medications. It exhibits rapid onset and severe progression, with a 30–35% mortality rate. 1 Toxic epidermal necrolysis can affect individuals of all ages and is linked to various medications and infections. Causative medications for TEN include antibiotics, anticonvulsants, sulphonamides and allopurinol. The typical clinical manifestations of TEN are widespread erythema, blistering and severe epidermal necrosis and detachment, sometimes leading to multi-organ involvement. Despite the growing understanding of the condition, consensus regarding the optimal treatment regimen for TEN remains elusive. Clinically, conventional treatments such as cyclophosphamide, cyclosporine and glucocorticoid (GC) therapy are often employed but are accompanied by significant side effects and an increased risk of infection. 2,3 Although previous literature has discussed using biological agents in treating adult patients with TEN, scant information exists regarding paediatric patients. 4 To date, only 4 children with toxic epidermal necrolysis have been treated with infliximab and 2 with etanercept. Andrea et al 5 reported an 8-year-old boy who was diagnosed with TEN induced by levetiracetam. He was first treated with methylprednisolone 1.5mg/kg/d and intravenous immunoglobulin 1g/kg/d for 5 consecutive days. However, significant progression and mucosal lesions were observed 2 days later, followed by etanercept at a dose of 0.8mg/kg (25mg), which stopped blistering within 24 hours after the use of etanercept, and the mucosal lesions were alleviated. Gavigan et al 6 reported an 11-year-old girl whose symptoms were significantly relieved after receiving methylprednisolone for 4 days 30mg/kg/d, cyclosporine 5mg/kg/d for 3 days, and 2 doses of etanercept 25mg every 24 hours. Although it has been reported that etanercept is effective in the treatment of TEN, there are still few reports about etanercept in the treatment of TEN in children. Therefore, it is necessary to explore the treatment of etanercept in children with TEN and summarize the clinical experience. In our department, we encountered a paediatric patient with TEN and effectively treated her using a combination therapy of etanercept (Yisaipu), GCs, and intravenous immunoglobulin (IVIG). Given the favourable outcomes, a detailed account of this case is provided in this report. A 7-year-old girl was admitted with the chief complaints of fever, rash and lip swelling for 2 days. Two days before admission, the patient developed an unprovoked fever, with the highest recorded temperature reaching 39.6°C. Initial fever management with ibuprofen failed to alleviate the symptoms. The patient did not experience chills or seizures. Subsequently, erythematous patchy skin rashes appeared on her face and ears, gradually spreading throughout her body. Concurrently, the patient developed blisters on her limbs and trunk and complained of itching on her hands and feet. Pronounced lip swelling was also noted (Figure 1A). The patient -Abstract Truncated-
dermatology